TRILUMINATE Pivotal - 2-year update EuroPCR 25, presented by G. Singh
The TRILUMINATE Pivotal trial demonstrated that TriClip™ TEER was superior to medical therapy alone at reducing Heart Failure Hospitalization (HFH) risk at 2 years, while confirming its exceptional safety and quality of life improvement
LEARN MORE:
Related Resources
Poster: Primary MR in the Very Elderly
Prognosis of TR after MitraClip for MR
bRIGHT 2-year real-world outcomes
ESC 2021: HF & VHD Guidelines
Data Summary PFO closure in patients > 60 Years
PCR LV 2021: Navitor™ 30-day outcomes
Navitor Valve in small aortic annuli
PCR LV 2021: Navitor™ Looking ahead
TRENDING TOPICS
Prognosis of TR after MitraClip for MR
Poster: Primary MR in the Very Elderly
bRIGHT 2-year real-world outcomes
